case_images: PMC6393887_01
case_images: MRI brain. (a) An axial, postcontrast-enhanced, fat-saturated T1-weighted image of the brain shows a 2.0 x 1.0 cm right parietal mass with ill-defined area of enhancement. (b) An axial, contrast enhanced, fat-saturated T1-weighted image of the brain, 3 weeks after therapy with cabozantinib, shows resolution of the prior mass and surrounding enhancement.
case_images: CRIU2019-6769017.001.jpg
case_images: PMC6393887_01_CRIU2019-6769017.001.jpg
case_images: fig1
case_images: Three weeks after starting cabozantinib, a repeat MRI brain was obtained for radiation planning and showed complete resolution of the right parietal mass with now encephalomalacia of the area (Figure 1).
case_images: CT CAP. (a) and (b) Axial images of CT CAP showed right sided hilar lymphadenopathy and a large left kidney mass. (c) and (d) Axial images of CT CAP showed improvement in right sided hilar lymphadenopathy and reduction in size of left kidney mass, after 8 weeks of therapy with cabozantinib.
case_images: CRIU2019-6769017.002.jpg
case_images: PMC6393887_01_CRIU2019-6769017.002.jpg
case_images: fig2
case_images: A CT CAP, obtained 8 weeks after initiation of cabozantinib therapy, showed partial response with reduction in size of mediastinal lymphadenopathy and bilateral renal masses (Figure 2).